PMC:7029759 / 26313-26510 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"631","span":{"begin":85,"end":93},"obj":"Species"},{"id":"636","span":{"begin":5,"end":11},"obj":"Chemical"},{"id":"637","span":{"begin":124,"end":130},"obj":"Chemical"},{"id":"650","span":{"begin":62,"end":66},"obj":"Disease"},{"id":"651","span":{"begin":70,"end":84},"obj":"Disease"}],"attributes":[{"id":"A631","pred":"tao:has_database_id","subj":"631","obj":"Tax:9606"},{"id":"A650","pred":"tao:has_database_id","subj":"650","obj":"MESH:D012128"},{"id":"A651","pred":"tao:has_database_id","subj":"651","obj":"MESH:D016638"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"CE2 (rhACE2) was moved into clinical trials in order to treat ARDS in critically ill patients. A phase I trial demonstrated rhACE2 was well tolerated with no effects seen on the cardiovascular syst"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T97","span":{"begin":62,"end":66},"obj":"Disease"}],"attributes":[{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"}],"text":"CE2 (rhACE2) was moved into clinical trials in order to treat ARDS in critically ill patients. A phase I trial demonstrated rhACE2 was well tolerated with no effects seen on the cardiovascular syst"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T240","span":{"begin":95,"end":96},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"CE2 (rhACE2) was moved into clinical trials in order to treat ARDS in critically ill patients. A phase I trial demonstrated rhACE2 was well tolerated with no effects seen on the cardiovascular syst"}